These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 22402257)

  • 21. Bleeding pattern with drospirenone 3 mg+ethinyl estradiol 20 mcg 24/4 combined oral contraceptive compared with desogestrel 150 mcg+ethinyl estradiol 20 mcg 21/7 combined oral contraceptive.
    Anttila L; Kunz M; Marr J
    Contraception; 2009 Nov; 80(5):445-51. PubMed ID: 19835718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cardiovascular risks associated with the use of drospirenone-containing combined oral contraceptives.
    Dinger J; Möhner S; Heinemann K
    Contraception; 2016 May; 93(5):378-85. PubMed ID: 26825258
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetics of drospirenone and ethinylestradiol in Caucasian and Japanese women.
    Blode H; Kowal K; Roth K; Reif S
    Eur J Contracept Reprod Health Care; 2012 Aug; 17(4):284-97. PubMed ID: 22680989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive.
    Keam SJ; Wagstaff AJ
    Treat Endocrinol; 2003; 2(1):49-70. PubMed ID: 15871554
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International Active Surveillance Study of Women Taking Oral Contraceptives.
    Dinger J; Bardenheuer K; Heinemann K
    Contraception; 2014 Apr; 89(4):253-63. PubMed ID: 24576793
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bleeding profile of a flexible extended regimen of ethinylestradiol/drospirenone in US women: an open-label, three-arm, active-controlled, multicenter study.
    Jensen JT; Garie SG; Trummer D; Elliesen J
    Contraception; 2012 Aug; 86(2):110-8. PubMed ID: 22281416
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of two contraceptive pills containing drospirenone and 20 μg or 30 μg ethinyl estradiol for polycystic ovary syndrome.
    Bhattacharya SM; Jha A; DasMukhopadhyay L
    Int J Gynaecol Obstet; 2016 Feb; 132(2):210-3. PubMed ID: 26613823
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ovarian function during low-dose oral contraceptive use.
    Egarter C; Putz M; Strohmer H; Speiser P; Wenzl R; Huber J
    Contraception; 1995 Jun; 51(6):329-33. PubMed ID: 7554971
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Folate status and homocysteine levels during a 24-week oral administration of a folate-containing oral contraceptive: a randomized, double-blind, active-controlled, parallel-group, US-based multicenter study.
    Bart S; Marr J; Diefenbach K; Trummer D; Sampson-Landers C
    Contraception; 2012 Jan; 85(1):42-50. PubMed ID: 22067790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cycle control with a 21-day compared with a 24-day oral contraceptive pill: a randomized controlled trial.
    Kaunitz AM; Burkman RT; Fisher AC; LaGuardia KD
    Obstet Gynecol; 2009 Dec; 114(6):1205-1212. PubMed ID: 19935020
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone.
    Bachmann G; Sulak PJ; Sampson-Landers C; Benda N; Marr J
    Contraception; 2004 Sep; 70(3):191-8. PubMed ID: 15325887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives.
    van Heusden AM; Fauser BC
    Contraception; 1999 Apr; 59(4):237-43. PubMed ID: 10457868
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Short-term effect of an estroprogestin containing ethinylestradiol 20 mcg + drospirenone 3 mg in 24+4 regimen at hormonal and cutaneous level in ovarian hyperandrogenism].
    Lello S; Pacifico V; Primavera G; Guardianelli F; Sorge R; Paoletti AM; Melis GB; Raskovic D; Colonna L
    Minerva Ginecol; 2010 Dec; 62(6):509-13. PubMed ID: 21079572
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nomegestrol acetate/estradiol: in oral contraception.
    Yang LP; Plosker GL
    Drugs; 2012 Oct; 72(14):1917-28. PubMed ID: 22950535
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A comparative randomized trial on the impact of two low-dose oral contraceptives on ovarian activity, cervical permeability, and endometrial receptivity.
    Rossmanith WG; Steffens D; Schramm G
    Contraception; 1997 Jul; 56(1):23-30. PubMed ID: 9306028
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Shorter pill-free interval in combined oral contraceptives decreases follicular development.
    Spona J; Elstein M; Feichtinger W; Sullivan H; Lüdicke F; Müller U; Düsterberg B
    Contraception; 1996 Aug; 54(2):71-7. PubMed ID: 8842582
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Contraceptive efficacy and tolerability of ethinylestradiol 20 μg/drospirenone 3 mg in a flexible extended regimen: an open-label, multicentre, randomised, controlled study.
    Klipping C; Duijkers I; Fortier MP; Marr J; Trummer D; Elliesen J
    J Fam Plann Reprod Health Care; 2012 Apr; 38(2):73-83. PubMed ID: 22454003
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum potassium monitoring for users of ethinyl estradiol/drospirenone taking medications predisposing to hyperkalemia: physician compliance and survey of knowledge and attitudes.
    Mona Eng P; Seeger JD; Loughlin J; Oh K; Walker AM
    Contraception; 2007 Feb; 75(2):101-7. PubMed ID: 17241838
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment.
    Thorneycroft lH; Gollnick H; Schellschmidt I
    Cutis; 2004 Aug; 74(2):123-30. PubMed ID: 15379365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.